Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | BUB1 | O43683 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15867796 | 0.81 | MAPK1 (0.33) | MAPK1NFKB1NFKB2RELACYP4F2 | |
| SCHEMBL5722406 | 0.79 | FFAR3 (0.39) | FFAR3MAPK1CYP4F2CYP4A11 | |
| SCHEMBL5663490 | 0.79 | MAPK1 (0.36) | MAPK1 | |
| SCHEMBL15722040 | 0.79 | MAPK1 (0.33) | MAPK1 | |
| SCHEMBL21564990 | 0.78 | FFAR3 (0.37) | FFAR3GAABUB1CYP4F2CYP4A11 | |
| SCHEMBL3880676 | 0.78 | FFAR3 (0.37) | FFAR3CYP4F2CYP4A11 | |
| SCHEMBL18821254 | 0.78 | CRBN (0.31) | — | |
| SCHEMBL24515274 | 0.77 | DGAT1 (0.32) | MAPK1 | |
| SCHEMBL29152537 | 0.77 | MAPK1 (0.34) | MAPK1 | |
| SCHEMBL7010046 | 0.75 | MAPK1 (0.37) | MAPK1GAANFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035388-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250084104-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2025-03-13 | — | — | US | disclosed |
| EP-4520328-A2 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2025-03-12 | — | — | EP | disclosed |
| US-12187743-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4219492-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2024-11-27 | — | — | EP | disclosed |
| CN-118908978-A | Tetrahydro-imidazo [4,5-c ] pyridine derivatives as PD-L1 immunomodulators | 因赛特公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-112752756-B | Tetrahydro-imidazo [4,5-c ] pyridine derivatives as PD-L1 immunomodulators | 因赛特公司 | 2024-06-25 | — | — | CN | disclosed |
| EP-4219492-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3790877-B1 | TETRAHYDRO-IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 IMMUNOMODULATORS | INCYTE CORP (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20220348594-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2022-11-03 | — | — | US | disclosed |
| WO-2020163823-A2 | THERAPEUTIC AGENTS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2020-08-13 | — | — | WO | disclosed |
| US-10618916-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2020-04-14 | — | — | US | disclosed |
| US-20190345170-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2019-11-14 | — | — | US | disclosed |
| EP-2576546-B1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE BAHAMAS LTD (BS) | 2015-07-22 | — | — | EP | disclosed |
| US-9034875-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-8580794-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130267514-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2013-10-10 | — | — | US | disclosed |
| EP-2576546-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbvie Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011149492-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20110124628-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084104-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | FFAR3 3572/4885MAPK1 3802/4885GAA 1924/4885 |
| US-10618916-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | FFAR3 3572/4885MAPK1 3802/4885GAA 1924/4885 |
| US-20260035388-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | IL2, IL4, NFATC1 | FFAR3 818/4885MAPK1 1679/4885GAA 3823/4885 |
| US-20220348594-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | FFAR3 3572/4885MAPK1 3802/4885GAA 1924/4885 |
| US-20130267514-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | FFAR3 3823/4885MAPK1 2721/4885GAA 2733/4885 |
| US-12187743-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | FFAR3 3572/4885MAPK1 3802/4885GAA 1924/4885 |
| US-20110124628-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | FFAR3 3823/4885MAPK1 2721/4885GAA 2733/4885 |
| US-20190345170-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | FFAR3 3572/4885MAPK1 3802/4885GAA 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.